Publication

The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects

Sipos, P. M., Loos, B. G., Abbas, F., Timmerman, M. F. & Velden, U. V. D., Jul-2005, In : Journal of Clinical Periodontology. 32, 7, p. 765-772 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Sipos, P. M., Loos, B. G., Abbas, F., Timmerman, M. F., & Velden, U. V. D. (2005). The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. Journal of Clinical Periodontology, 32(7), 765-772. https://doi.org/10.1111/j.1600-051X.2005.00754.x

Author

Sipos, P.M. ; Loos, B.G. ; Abbas, F. ; Timmerman, M.F. ; Velden, U. van der. / The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. In: Journal of Clinical Periodontology. 2005 ; Vol. 32, No. 7. pp. 765-772.

Harvard

Sipos, PM, Loos, BG, Abbas, F, Timmerman, MF & Velden, UVD 2005, 'The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects', Journal of Clinical Periodontology, vol. 32, no. 7, pp. 765-772. https://doi.org/10.1111/j.1600-051X.2005.00754.x

Standard

The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. / Sipos, P.M.; Loos, B.G.; Abbas, F.; Timmerman, M.F.; Velden, U. van der.

In: Journal of Clinical Periodontology, Vol. 32, No. 7, 07.2005, p. 765-772.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Sipos PM, Loos BG, Abbas F, Timmerman MF, Velden UVD. The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. Journal of Clinical Periodontology. 2005 Jul;32(7):765-772. https://doi.org/10.1111/j.1600-051X.2005.00754.x


BibTeX

@article{ffabd6b63b49475ebe0f79529991afe1,
title = "The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects",
abstract = "Objectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel((R))) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex((R))).Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86 +/- 0.75 mm, a mean gain in CAL of 1.28 +/- 2.04 mm, a mean PBL gain of 1.63 +/- 1.21 mm and a mean increase of recession (REC) of 1.56 +/- 2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02 +/- 1.55 mm, a mean gain in CAL of 1.65 +/- 1.29 mm, a mean PBL gain of 1.58 +/- 1.92 mm and a mean increase of REC of 1.38 +/- 1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.",
keywords = "barrier membranes, enamel matrix proteins, GTR, intra-osseous defects, tetracycline, GUIDED TISSUE REGENERATION, INTRABONY PERIODONTAL DEFECTS, CONTROLLED CLINICAL-TRIAL, NON-RESORBABLE BARRIERS, ANGULAR BONE DEFECTS, IN-VITRO, BIOABSORBABLE MEMBRANES, DERIVATIVE EMDOGAIN(R), BACTERIAL-COLONIZATION, ANAEROBIC-BACTERIA",
author = "P.M. Sipos and B.G. Loos and F. Abbas and M.F. Timmerman and Velden, {U. van der}",
note = "Relation: https://www.rug.nl/ date_submitted:2007 Rights: University of Groningen",
year = "2005",
month = jul,
doi = "10.1111/j.1600-051X.2005.00754.x",
language = "English",
volume = "32",
pages = "765--772",
journal = "Journal of Clinical Periodontology",
issn = "0303-6979",
publisher = "Wiley",
number = "7",

}

RIS

TY - JOUR

T1 - The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects

AU - Sipos, P.M.

AU - Loos, B.G.

AU - Abbas, F.

AU - Timmerman, M.F.

AU - Velden, U. van der

N1 - Relation: https://www.rug.nl/ date_submitted:2007 Rights: University of Groningen

PY - 2005/7

Y1 - 2005/7

N2 - Objectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel((R))) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex((R))).Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86 +/- 0.75 mm, a mean gain in CAL of 1.28 +/- 2.04 mm, a mean PBL gain of 1.63 +/- 1.21 mm and a mean increase of recession (REC) of 1.56 +/- 2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02 +/- 1.55 mm, a mean gain in CAL of 1.65 +/- 1.29 mm, a mean PBL gain of 1.58 +/- 1.92 mm and a mean increase of REC of 1.38 +/- 1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.

AB - Objectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel((R))) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex((R))).Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86 +/- 0.75 mm, a mean gain in CAL of 1.28 +/- 2.04 mm, a mean PBL gain of 1.63 +/- 1.21 mm and a mean increase of recession (REC) of 1.56 +/- 2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02 +/- 1.55 mm, a mean gain in CAL of 1.65 +/- 1.29 mm, a mean PBL gain of 1.58 +/- 1.92 mm and a mean increase of REC of 1.38 +/- 1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.

KW - barrier membranes

KW - enamel matrix proteins

KW - GTR

KW - intra-osseous defects

KW - tetracycline

KW - GUIDED TISSUE REGENERATION

KW - INTRABONY PERIODONTAL DEFECTS

KW - CONTROLLED CLINICAL-TRIAL

KW - NON-RESORBABLE BARRIERS

KW - ANGULAR BONE DEFECTS

KW - IN-VITRO

KW - BIOABSORBABLE MEMBRANES

KW - DERIVATIVE EMDOGAIN(R)

KW - BACTERIAL-COLONIZATION

KW - ANAEROBIC-BACTERIA

U2 - 10.1111/j.1600-051X.2005.00754.x

DO - 10.1111/j.1600-051X.2005.00754.x

M3 - Article

VL - 32

SP - 765

EP - 772

JO - Journal of Clinical Periodontology

JF - Journal of Clinical Periodontology

SN - 0303-6979

IS - 7

ER -

ID: 2913241